Výsledky vyhledávání - "Francis Mogollon-Duffo"

Akademický článek

Nivolumab as salvage treatment in a patient with HIV-related relapsed/refractory Hodgkin lymphoma and liver failure with encephalopathy

Autor: Jose D. Sandoval-Sus, Francis Mogollon-Duffo, Ankita Patel, Nathan Visweshwar, Damian A. Laber, Richard Kim, Michael V. Jagal

Publikováno v: Journal for ImmunoTherapy of Cancer, Vol 5, Iss 1, Pp 1-5 (2017)

Abstract Background We report the first case to our knowledge of a patient with relapsed/refractory classical hodgkin lymphoma and liver failure with encephalopathy along with human immunodeficiency virus/acquired immunodeficiency syndrome infection,

Externí odkaz: https://doaj.org/article/e9969ef5810c4a8882d4c229641e3e4e

Zobrazit plný text záznamu

Case report: Minimal change disease and acute interstitial nephritis in a patient with Hodgkin’s lymphoma treated with nivolumab

Autor: Elie R. Chemaly, Ramon Lopez del Valle, Jose Sandoval Sus, Jacques A. Durr, Damian A. Laber, Mazdak A Khalighi, Francis Mogollon-Duffo, Faizul Hussain

Publikováno v: Journal of Onco-Nephrology. 4:81-86

Programmed cell death receptor-1 blocking antibodies and cytotoxic T-lymphocyte–associated antigen-4 blocking antibodies are referred to as checkpoint inhibitors and are used in cancer immunotherapy. While enhancing T-cell antitumor immunity, check

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a1cf72487f9e86051d8c1e2e7580d599
https://doi.org/10.1177/2399369320927717

Zobrazit plný text záznamu

Abstract P3-11-24: Relative risk of peripheral neuropathy with trastuzumab emtansine compared to taxane-based regimens in HER2-positive cancers: A systematic review and meta-analysis of published phase 3 randomized controlled trials

Autor: Lukman Tijani, Rafiullah Khan, Nusrat Jahan, Catherine Jones, Shabnam Rehman, Somedeb Ball, Francis Mogollon-Duffo

Publikováno v: Cancer Research. 80:P3-11

Background: Trastuzumab Emtansine (T-DM1) is a HER2-targeted antibody-drug conjugate consisting of anti-HER2 IgG1 antibody trastuzumab and maytansine derivative DM-1. The trastuzumab part of T-DM1 inhibits HER2 receptor signaling, mediates antibody-d

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::2017c26a850bdb0b70a22836cd237f97
https://doi.org/10.1158/1538-7445.sabcs19-p3-11-24

Zobrazit plný text záznamu

Abstract P5-14-10: Relative risk of grade 3 and higher hematological toxicities with trastuzumab emtansine: A systematic review and meta-analysis of published phase 3 randomized controlled trials

Autor: Rafiullah Khan, Lukman Tijani, Shabnam Rehman, Nusrat Jahan, Fred Hardwicke, Francis Mogollon-Duffo

Publikováno v: Cancer Research. 80:P5-14

Background: Trastuzumab Emtansine (T-DM1) is a HER2 targeted antibody-drug conjugate consisting of anti-HER2 IgG1 antibody trastuzumab and maytansine derivative DM-1. Trastuzumab inhibits HER2 receptor signaling and mediates antibody-dependent cell-m

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::81a968e4983dd0df1fb13a4b7ab7b79b
https://doi.org/10.1158/1538-7445.sabcs19-p5-14-10

Zobrazit plný text záznamu

CLO19-051: CDK 4/6 Inhibitor-Associated Hematologic Toxicities and Febrile Neutropenia in Patients With Hormone Receptor-Positive HER2-Negative Metastatic Breast Cancer

Autor: Yin Mon Myat, Somedeb Ball, Nimesh Adhikari, Catherine Jones, Anita Sultan, Sriman Swarup, Kyaw Zin Thein, Myo H. Zaw, Francis Mogollon-Duffo

Publikováno v: Journal of the National Comprehensive Cancer Network. 17:CLO19-051

Background: Breast cancer is the most common cancer in women, and the majority of breast cancers express the estrogen receptor or progesterone receptor. Inhibition of CDK4/6 signaling pathway has shown survival benefit in advanced breast cancer by ov

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::d4b0b4bbc0fbf3cefb2dea7c939c61ca
https://doi.org/10.6004/jnccn.2018.7152

Zobrazit plný text záznamu

EPR19-74: Risk of Cabozantinib-Associated Gastrointestinal and Hepatic Toxicities in Patients With Metastatic Solid Tumors: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Autor: Myo H. Zaw, Anita Sultan, Ye Aung, Sriman Swarup, Kyaw Zin Thein, Rachana Yendala, Nicholas D'Cunha, Francis Mogollon-Duffo, Yin Mon Myat

Publikováno v: Journal of the National Comprehensive Cancer Network. 17:EPR19-74

Background: Cabozantinib is an oral inhibitor of multiple tyrosine kinases and is used in treatment of multiple solid tumors, targeting several pathways such as vascular endothelial growth factor signaling pathway and proto-oncogenes MET, KIT, RET. T

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::332243a922627cc3d770dde473a497b1
https://doi.org/10.6004/jnccn.2018.7155

Zobrazit plný text záznamu

Relative risk of HTN and major cardiovascular events associated with use of androgen receptor antagonists for nonmetastatic, castration-resistant prostate cancer

Autor: Sakshi Singal, Nusrat Jahan, Francis Mogollon-Duffo, Shabnam Rehman, Fred Hardwicke

Publikováno v: Journal of Clinical Oncology. 38:e17605-e17605

e17605 Background: Metastatic, castration-resistant prostate cancer (mCRPC) is a lethal disease, often preceded by nonmetastatic, castration-resistant phase. Recently, three androgen receptor (AR) antagonists — apalutamide, enzalutamide, and darolu

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::3497f571eb4ee60f6e2d28f5ab1c0c2b
https://doi.org/10.1200/jco.2020.38.15_suppl.e17605

Zobrazit plný text záznamu

Efficacy of androgen receptor antagonists in combination with androgen deprivation therapy in nonmetastatic, castration-resistant prostate cancer: A systematic review and meta-analysis of published phase III randomized controlled trials

Autor: Francis Mogollon-Duffo, Sariya Wongsaengsak, Shabnam Rehman, Nusrat Jahan, Somedeb Ball, Lukman Aderoju Tijani

Publikováno v: Journal of Clinical Oncology. 38:e17606-e17606

e17606 Background: Nonmetastatic, castration-resistant prostate cancer (nmCRPC) often heralds metastatic disease which is responsible for majority of the morbidity and mortality associated with prostate cancer. Hence, delaying metastasis is an expedi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::0717b587a880219d5529996cd49de4fc
https://doi.org/10.1200/jco.2020.38.15_suppl.e17606

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání